VP75 Improving Access To Ultra-Orphan Medicines In NHS Scotland

• Published in: International journal of technology assessment in health care 2019, Vol.35 (S1), p.93-93
• Main Authors: Downes, Noreen, Jones, Jan, Lee, Anne, Brown, Ailsa, McGuire, Pauline, Wright, Helen
• Format: Article
• Language: English
• Subjects: Clinical decision making; Clinical trials; Data collection; Decision making; Medicine; Pharmaceutical industry; Pharmaceuticals
• ISSN: 0266-4623; 1471-6348
• DOI: 10.1017/S0266462319003301

Copyright © Cambridge University Press 20192019Cambridge University PressIntroductionMedicines for very rare conditions present challenges for healthcare globally due to uncertain evidence and often extremely high costs. In 2014, SMC introduced an ultra-orphan framework placing less emphasis on the cost per quality adjusted life year (QALY). Despite this, many medicines continued to be not recommended. A new pathway aimed at improved patient access based on further evidence collection is now being implemented.MethodsThe development of the new pathway has involved collaboration with key stakeholders including patient groups, the pharmaceutical industry, and clinicians. Medicines that meet a new definition (based on four criteria including the prevalence of the condition treated) will be appraised by the SMC committee and a data collection plan will then be agreed with the pharmaceutical company.ResultsFrom April 2019, medicines validated as ultra-orphans will initially be appraised using the broader decision-making framework and the SMC committee will outline key uncertainties in the clinical effectiveness. The medicine will then be available for a period of at least three years while further data are gathered, potentially comprising ongoing clinical trials, registry data, and patient reported outcome measures. SMC will then re-assess the clinical and economic evidence to inform a final decision on routine use of the medicine in NHS Scotland.ConclusionsThe new pathway for ultra-orphan medicines will allow further evidence on their longer-term clinical benefits to be collected before a final decision on routine use. This approach reflects the current direction of travel in medicines regulation, by making medicines that address an unmet need available to patients at an earlier stage of development.